Carotuximab - TRACON Pharmaceuticals

Drug Profile

Carotuximab - TRACON Pharmaceuticals

Alternative Names: CD-105; Chimeric Antibody TRC105; DE-122; NSC#754227; TRC-105

Latest Information Update: 08 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roswell Park Cancer Institute
  • Developer National Cancer Institute (USA); Santen Pharmaceutical; TRACON Pharmaceuticals; University of Alabama at Birmingham; University of Minnesota
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; ENG protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemangiosarcoma
  • Phase II Choriocarcinoma; Glioblastoma; Hepatocellular carcinoma; Renal cell carcinoma; Soft tissue sarcoma; Wet age-related macular degeneration
  • Phase I/II Breast cancer
  • Phase I Non-small cell lung cancer
  • Preclinical Acute myeloid leukaemia; Colorectal cancer; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Discontinued Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer

Most Recent Events

  • 01 Feb 2018 Cedars-Sinai Medical Center plans a phase II trial for Prostate Cancer (Late-stage disease) in USA , (NCT03418324)
  • 20 Jan 2018 Efficacy and adverse events data from a phase Ib/II trial in Hepatocellular carcinoma released by TRACON Pharmaceuticals
  • 21 Dec 2017 Carotuximab licensed to Ambrx for all indication, excluding ophthalmology in China, Hong-Kong, Macau and Taiwan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top